首页> 美国卫生研究院文献>other >Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model
【2h】

Tissue-Engineered Small Diameter Arterial Vascular Grafts from Cell-Free Nanofiber PCL/Chitosan Scaffolds in a Sheep Model

机译:绵羊模型中无细胞纳米纤维PCL /壳聚糖支架的组织工程小直径动脉血管移植。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tissue engineered vascular grafts (TEVGs) have the potential to overcome the issues faced by existing small diameter prosthetic grafts by providing a biodegradable scaffold where the patient’s own cells can engraft and form functional neotissue. However, applying classical approaches to create arterial TEVGs using slow degrading materials with supraphysiological mechanical properties, typically results in limited host cell infiltration, poor remodeling, stenosis, and calcification. The purpose of this study is to evaluate the feasibility of novel small diameter arterial TEVGs created using fast degrading material. A 1.0mm and 5.0mm diameter TEVGs were fabricated with electrospun polycaprolactone (PCL) and chitosan (CS) blend nanofibers. The 1.0mm TEVGs were implanted in mice (n = 3) as an unseeded infrarenal abdominal aorta interposition conduit., The 5.0mm TEVGs were implanted in sheep (n = 6) as an unseeded carotid artery (CA) interposition conduit. Mice were followed with ultrasound and sacrificed at 6 months. All 1.0mm TEVGs remained patent without evidence of thrombosis or aneurysm formation. Based on small animal outcomes, sheep were followed with ultrasound and sacrificed at 6 months for histological and mechanical analysis. There was no aneurysm formation or calcification in the TEVGs. 4 out of 6 grafts (67%) were patent. After 6 months in vivo, 9.1 ± 5.4% remained of the original scaffold. Histological analysis of patent grafts demonstrated deposition of extracellular matrix constituents including elastin and collagen production, as well as endothelialization and organized contractile smooth muscle cells, similar to that of native CA. The mechanical properties of TEVGs were comparable to native CA. There was a significant positive correlation between TEVG wall thickness and CD68+ macrophage infiltration into the scaffold (R2 = 0.95, p = 0.001). The fast degradation of CS in our novel TEVG promoted excellent cellular infiltration and neotissue formation without calcification or aneurysm. Modulating host macrophage infiltration into the scaffold is a key to reducing excessive neotissue formation and stenosis.
机译:组织工程化的血管移植物(TEVG)有潜力通过提供一种可生物降解的支架来克服现有的小直径义齿移植物所面临的问题,在这种支架中,患者自己的细胞可以移植并形成功能性新组织。然而,使用具有超生理学机械特性的慢速降解材料,应用经典方法创建动脉TEVG,通常会导致宿主细胞浸润受限,重塑,狭窄和钙化。这项研究的目的是评估使用快速降解材料制成的新型小直径动脉TEVG的可行性。用电纺聚己内酯(PCL)和壳聚糖(CS)共混纳米纤维制造了直径为1.0mm和5.0mm的TEVG。将1.0mm TEVGs作为无种子的肾下腹主动脉插入导管植入小鼠(n = 3)。将5.0mm TEVGs作为无种子的颈动脉(CA)插入导管植入绵羊(n = 6)中。对小鼠进行超声检查并在6个月时处死。所有1.0mm TEVG均保持专利,没有血栓形成或动脉瘤形成的迹象。根据小动物的结局,对绵羊进行超声检查,并在6个月时处死以进行组织学和力学分析。 TEVGs中没有动脉瘤形成或钙化。 6个移植物中有4个(67%)获得专利。在体内6个月后,保留了原始支架的9.1±5.4%。专利移植物的组织学分析表明,胞外基质成分的沉积,包括弹性蛋白和胶原蛋白的生成,以及内皮化和组织性收缩性平滑肌细胞的生成,与天然CA相似。 TEVG的机械性能与天然CA相当。 TEVG壁厚与CD68 + 巨噬细胞向支架的浸润之间存在显着正相关(R 2 = 0.95,p = 0.001)。 CS在我们的新型TEVG中的快速降解促进了优异的细胞浸润和新组织形成,而没有钙化或动脉瘤。调节宿主巨噬细胞向支架的浸润是减少过多的新组织形成和狭窄的关键。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号